Check for updates

OPEN ACCESS

EDITED BY Robert Breiman, Emory University, United States

REVIEWED BY Mingzhu Li, Peking University People's Hospital, China Admire Takuranenhamo Chikandiwa, Wits Health Consortium (WHC), South Africa

*CORRESPONDENCE Lin Zeng Zenglinwa@outlook.com

RECEIVED 12 December 2024 ACCEPTED 25 March 2025 PUBLISHED 17 April 2025

CITATION

He J, Tu lu Weng Jiang G and Zeng L (2025) Analysis of the differences between HPV-independent and HPV-related cervical adenocarcinoma. *Front. Oncol.* 15:1544207. doi: 10.3389/fonc.2025.1544207

COPYRIGHT

© 2025 He, Tu lu Weng Jiang and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Analysis of the differences between HPV-independent and HPV-related cervical adenocarcinoma

Jing He¹, Gulixian Tu lu Weng Jiang² and Lin Zeng^{1*}

¹Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China, ²Department of Critical Care Medicine, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China

Background: No prognostic evaluation criteria have been established for either human papillomavirus (HPV)-related cervical adenocarcinoma (HPV-CA) or HPV-independent cervical adenocarcinoma (HPV-Ind-CA). We aimed to compare and analyze the clinicopathological features and survival prognosis of patients with HPV-related and HPV-independent cervical adenocarcinoma to facilitate clinical diagnosis, treatment and survival prognosis of patients with cervical adenocarcinoma.

Methods: Clinical data were collected from 47 patients with HPV-Ind-CA (HPV-Ind-CA group) and 285 patients with HPV-CA (HPV-CA group), who were diagnosed at the Oncology Hospital affiliated with Xinjiang Medical University between October 2012 and July 2023. A retrospective analysis was performed to compare the clinical characteristics (including age, ethnicity, fundamental diseases, initial symptoms, gynecological examination findings such as contact bleeding, menstrual history with regard to menopausal status, history of pregnancy and abortion, coexisting benign uterine lesions, etc.), tumor markers (CEA, CA125, CA199), HPV-infection(HPVI), treatment regimens (surgery, radiotherapy and chemotherapy), and pathological results (specific pathological subtype, maximum lesion diameter, degree of tumor differentiation, International Federation of Gynecology and Obstetrics [FIGO] stage) between the two groups. All patients were followed up until July 30, 2023 and differences in therapeutic efficacy (complete response, stable disease, progressive disease) and survival outcomes (progression-free survival [PFS] and overall survival [OS]) were compared between the two patient groups following treatment.

Results: The proportions of patients in the HPV-Ind-CA and HPV-CA groups were 14.2% and 85.8%, respectively. Most patients presented with irregular vaginal bleeding, and a significant number experienced contact bleeding. The patients in the HPV-Ind-CA group were older (\geq 50 years), had a lower degree of differentiation, a later FIGO stage (> I stage), higher CA125 levels, and constituted a greater number of postmenopausal patients (P < 0.05) than those in the HPV-CA group. The median PFS and OS in the HPV-Ind-CA group were 12 ± 25.5 and 21 ± 25.1 months, respectively; the 3-year OS and PFS rates were 70.21%, and 59.57%, respectively. In contrast, the median PFS in the HPV-CA group was significantly longer at 26 ± 32.3 months, with a corresponding median OS of 35 ± 31.9 months; their respective 3-year OS and PFS rates were 80.70% and 73.68%.

The HPV-Ind-CA group demonstrated significantly shorter PFS and OS than the HPV-CA group (P < 0.05). In the HPV-Ind-CA cohort, low cervical adenocarcinoma differentiation (HR=152.673, 95% CI: 1.777–13117.314, P=0.027) and high CA199 levels (HR=104.888, 95%CI: 2.420–4546.373, P=0.016) were independent prognostic factors for OS. Conversely, in the HPV-CA cohort, the FIGO stage (> stage I), absence of HPVI, and high CA125 levels were independent prognostic factors influencing both OS and PFS outcomes; additionally, older age \geq 50 years and high CA199 levels were independent risk factors for OS and PFS, respectively. Thus, greater than stage I FIGO stage and high CA125 and CA199 levels were identified as independent prognostic factors for PFS and OS in cervical adenocarcinoma. Furthermore, the absence of HPVI and older age of \geq 50 years also constituted as independent risk factors for OS in this patient population.

Conclusions: Compared with HPV-CA, HPV-Ind-CA is associated with inferior clinicopathological characteristics and survival outcomes. For patients who are HPV-negative and have elevated levels of CA125 and CA199, with a FIGO stage of I or higher, it is advisable to contemplate an intensified treatment protocol. This approach aims to enhance the opportunity for curative surgical resection when the patient's physical condition permits it, thereby improving the overall prognosis.

KEYWORDS

cervical adenocarcinoma, HPV-related cervical adenocarcinoma, HPV-independent cervical adenocarcinoma, prognosis, retrospective cohort study

1 Introduction

Cervical cancer is one of the most prevalent gynecological malignancies and the fourth most common neoplasm worldwide. In 2018, approximately 570,000 new cancer cases were reported worldwide, accounting for 6.6% of all cancer cases diagnosed in women (1). In developing countries, the incidence and mortality of cervical cancer occupy the second position; whereas in developed countries, it ranks the tenth (2). Epidemiological studies have demonstrated that the incidence and mortality rates of cervical cancer in China are among the highest globally, imposing a substantial disease burden on the population (3, 4). The most prevalent type is cervical squamous cell carcinoma (SCC) associated with human papillomavirus (HPV)-infection (HPVI) (5). Adenocarcinomas account for approximately 25% of cervical cancer cases, of which approximately 15% are unrelated to HPV (6). The prevalence of HPVI in patients with invasive cervical cancer

ranges from 85% to 99%. High-risk HPV types 16 and 18 comprise approximately 70-80% of SCC, whereas HPV types 16, 18, and 45 account for approximately 94% of cervical adenocarcinomas (7). In recent years, with the widespread implementation of cervical cancer screening programs, the incidence of squamous epithelial lesions has consistently decreased, whereas that of glandular epithelial lesions has continuously increased (8). In 2020, the fifth edition of the World Health Organization revised the classification of cervical adenocarcinoma based on the International Endocervical Adenocarcinoma Criteria and Classification (IECC) and its association with HPV. Cervical adenocarcinomas are categorized into two primary types: HPV-related and HPV-independent (9). Usual type and mucinous cervical adenocarcinoma (specifically the intestinal type, signet ring cell type) is the most commonly encountered type of HPV-related cervical adenocarcinoma (HPV-CA). Other subtypes of HPV-CA encompass invasive stratified mucinous carcinoma (ISMC) as well as non-specific mucinous adenocarcinoma. HPV-Independent cervical adenocarcinoma (HPV-Ind-CA) includes gastric-type adenocarcinoma (G-EAC), clear-cell carcinoma, mesonephric adenocarcinoma, endometrioid adenocarcinoma, and non-specific adenocarcinoma (8, 9).

Currently, research on cervical adenocarcinoma represents a significant area of interest, as existing guidelines do not differentiate treatment approaches for these lesions from those applicable to squamous lesions. However, increasing evidence suggests that the

Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; G-EAC, gastric-type adenocarcinoma; IECC, International Endocervical Adenocarcinoma Criteria and Classification; ISMC, invasive stratified mucinous carcinoma; HPV-CA, HPV-related adenocarcinoma; HPVI, human papillomavirus (HPV)-infection; HPV-Ind -CA, HPV-independent adenocarcinoma; OS, overall survival; PFS, progression-free survival; SCC, squamous cell carcinoma.

biological behavior, therapeutic outcomes, and prognostic factors associated with cervical adenocarcinoma are distinct from those associated with SCC. Furthermore, cervical adenocarcinomas exhibit reduced sensitivity to radiotherapy and chemotherapy and are associated with poorer prognoses than SCC (10). Moreover, to date, no prognostic evaluation criteria have been established for HPV-CA or HPV-Ind-CA globally. Consequently, an examination of the differences in the clinical and pathological characteristics between patients with HPV-Ind-CA and those with HPV-CA is of considerable significance for clinical diagnosis and treatment outcomes.

This study aimed to comparatively analyze the clinicopathological characteristics, therapeutic efficacy assessments, and survival prognoses of the HPV-CA and HPV-Ind-CA groups to further investigate the key factors influencing prognosis, recurrence, and metastasis with the aim of providing valuable insights into the diagnosis and treatment of such patients in clinical practice.

2 Materials and methods

2.1 Study population

Data were collected from 332 patients diagnosed (through radical surgery/biopsy/resection specimens) with cervical adenocarcinoma at the Oncology Hospital affiliated with Xinjiang Medical University between October 2012 and July 2023 and categorized into the HPV-Ind-CA and HPV-CA groups. Diagnosis was established in accordance with the World Health Organization classification criteria for adenocarcinoma published in 2020. The HPV-CA group included well-differentiated adenocarcinoma and mucinous adenocarcinoma (intestinal type, ISMC, and nonspecific mucinous adenocarcinoma), whereas the HPV-Ind -CA group included G-EAC, clear cell carcinoma, endometrioid adenocarcinoma, and nonspecific invasive adenocarcinoma. The HPV-Ind-CA group comprised 14.2% (47/ 332) and the HPV-CA group comprised 85.8% (285/332) of the participants. A retrospective comparative analysis was conducted to evaluate differences in clinicopathological characteristics, auxiliary examination results, treatment modalities, prognostic outcomes, and survival rates between the two groups.

2.2 Monitoring of survival

All patients were followed up through outpatient consultations and telephone communication. Among the participants, four were lost to follow-up, resulting in an overall follow-up rate of 97.32%. The follow-up duration varied from 2 to 217 months, with a median of 37 months. Statistical analysis of therapeutic outcomes included complete remission (CR), stable disease (SD), disease progression (PD), and mortality. We evaluated overall survival (OS) from diagnosis until patient death and progression-free survival (PFS) from diagnosis to PD.

2.3 Statistical analysis

Data were analyzed utilizing SPSS 26.0 statistical software. Categorical data were subjected to the chi-square test and are expressed as percentages (%). Survival curves were evaluated using the Kaplan–Meier method, and differences in PFS and OS between the two groups were compared using log-rank regression analysis. The Cox proportional hazards model was used for prognostic factor analysis. Statistical significance was set at P < 0.05.

3 Results

3.1 Basic clinical characteristics

The age at diagnosis of the 332 patients with cervical adenocarcinoma ranged from 27 to 82 years, with a mean age of 52 years. There was no significant disparity between the two groups of patients regarding underlying diseases, such as heart disorders, vascular disorders and diabetes mellitus (Table 1). The predominant concern among the patients with cervical adenocarcinoma at the time of medical consultation was abnormal vaginal bleeding and discharge (71.7%, 238/332). Additionally, 65.4% (217/332) of patients experienced contact bleeding (Table 1). The overall HPVI rate among patients was 65.36% (217/332), with 10.6% (5/47) in the HPV-Ind-CA group and 74.4% (212/285) in the HPV-CA group. The median age at diagnosis of patients with cervical adenocarcinoma was 56 years in the HPV-Ind-CA group and 51 years in the HPV-CA group. Statistical analysis indicated a significant difference between the two groups ($\chi^2 = 11.166$, P = 0.001). The maximum tumor diameter ranged from 0.5 to 12.9 cm, with a mean of 4.6 cm. Among them, 70.2% (233/332) underwent radical hysterectomy for cervical cancer. Excluding age as a variable, statistically significant differences were observed between the HPV-Ind-CA and HPV-CA groups regarding menstrual history (menopausal status), FIGO stage, variations in tumor markers (CA125), performance of radical surgery, and degree of differentiation (P< 0.05). The HPV-Ind-CA group exhibited older age, greater FIGO stage, lower degree of differentiation, higher CA125 levels, and a higher proportion of postmenopausal patients, as well as those not suitable for radical surgery, than the HPV-CA group (P < 0.05). Conversely, no statistically significant differences were observed between the two groups in terms of ethnicity, initial symptoms, presence of contact bleeding, coexisting benign uterine lesions (adenomyosis, leiomyoma, and ectopic pregnancy), variations in tumor markers (CA199 and CEA), treatment modalities

Basic clinical characteristics	HPV-Ind-CA group	HPV-CA group	χ²/fisher	Р
Age, years				
≥50	37	150	11.166	0.001*
<50	10	135		
Asian ethnicity				
Han	32	201	7.673	0.362
Hui	6	12		
Uigur	9	59		
Manchu	0	3		
Kirgiz	0	1		
Kazak	0	6		
Mongolian	0	2		
Dongxiang	0	1		
Symptoms				
Abnormal vaginal hemorrhage	28	164	3.034	0.882
Abnormal vaginal secretion	7	39		
Other	1	20		
None	13	89		
Vascular disorders				
Yes	9	48		
No	36	226	0.162	0.687
Cardiac disorders				
Yes	9	41		
No	36	233	0.742	0.389
Diabetes mellitus				
Yes	7	19		
No	38	255	3.838	0.050
Parity				
<2	11	38	3.391	0.066
≥2	35	244		
Miscarriage incidence				
<2	30	174	0.234	0.629
≥2	16	109		
Menopause				
Yes	33	150	5.738	0.017*
No	13	134		
Bleeding $^{ riangle}$				
Yes	27	190	1.515	0.218
No	20	95		
		1		

TABLE 1 Basic clinical characteristics of patients diagnosed with cervical adenocarcinoma in the two groups.

(Continued)

TABLE 1 Continued

Basic clinical characteristics	HPV-Ind-CA group	HPV-CA group	χ^2 /fisher	Р			
Correlation with other benign uterine lesions							
Adenomyoma	3	19	5.958	0.202			
Leiomyoma	9	96					
Ectopic gestation	0	2					
No	37	178					
HPVI							
Yes	5	212					
No	42	73	-	-			

HPV-CA, human papillomavirus-related cervical adenocarcinoma; HPVI, human papillomavirus infection; HPV-Ind-CA, human papillomavirus-independent cervical adenocarcinoma; ^(A)denotes the occurrence of contact hemorrhage. *P<0.05.

(radiotherapy and chemotherapy), presence of HPVI, or maximum tumor diameter (P > 0.05; Tables 1-3).

3.2 Pathological characteristics

The predominant pathological type was usual type cervical adenocarcinoma, comprising 76.8% (255/332) of cases. Other subtypes of HPV-CA included 20 (6.02%) of mucinous adenocarcinoma, not otherwise specified(NOS)、 9 (2.71%) of intestinal-type mucinous adenocarcinoma and 1 (0.30%) of ISMC. Within the HPV-Ind-CA group, the predominant subtype was gastric-type adenocarcinoma, which included three cases of micro invasive adenocarcinoma and constituted 9.04% of all cases. Other subtypes of HPV-Ind-CA included 7 (2.11%) of invasive adenocarcinoma, NOS、 6 cases (1.81%) of endometrioid adenocarcinoma and 4 (1.20%) of clear cell carcinoma. A total of 65.4% (217/332) of patients tested positive for HPV, with only 31.63% (153/178) classified as having FIGO stage I. Most patients exhibited cervical masses, and 75.30% (250/332) had tumors with a maximum diameter of at least 2 cm. The distribution of patients by

grade of cervical adenocarcinoma was as follows: high-grade, 11.45%; moderate-grade, 64.46%; and low-grade, 24.10% (Table 4).

3.3 Assessment of treatment efficacy and survival analysis

No significant differences were observed in the efficacy assessment (CR, SD, and PD) between the two patient groups (P > 0.05), and there was no statistically significant difference in the proportion of patients who succumbed to tumors in either group (Table 5). The log-rank univariate analysis indicated that factors such as older age of \geq 50 years, presence of contact bleeding, postmenopausal status, absence of HPVI, high levels of serum tumor markers (CA125, CA199, CEA), lack of radical surgery, FIGO stage > I, and low differentiation were identified as risk factors for OS and PFS in patients with cervical adenocarcinoma. Furthermore, patients with a maximum tumor diameter \geq 2 cm exhibited significantly shorter PFS (P < 0.05), as detailed in Table 6 and Figure 1.

In summary, multivariate Cox regression analysis revealed that FIGO stage > I and high levels of CA125 and CA199 were

TABLE 2 A comparative analysis of the alterations in tumor markers between the two patient groups.

Index	HPV-Ind-CA group	HPV-CA group	χ^2 /fisher	Р			
CA125							
Increase	25	110	4.477	0.034*			
Normal	19	166					
CA199	CA199						
Increase	16	68	2.387	0.122			
Normal	29	208					
CEA							
Increase	12	71	0.006	0.936			
Normal	33	201					

HPV-CA, human papillomavirus-related cervical adenocarcinoma; HPV-Ind-CA, human papillomavirus-independent cervical adenocarcinoma; *P<0.05.

Clinical Treatment Protocols	HPV-Ind-CA group	HPV-CA group	χ^2 /fisher	Р		
Surgery						
Yes	22	211	14.955	0.000*		
No	25	72				
Adjuvant radiotherapy						
Yes	35	177	5.350	0.069		
No	11	107				
Adjuvant chemotherapy						
Yes	32	188	0.014	0.800		
No	15	96				

TABLE 3 A comparative analysis of the treatment protocols between the two patient groups.

HPV-CA, human papillomavirus-related cervical adenocarcinoma; HPV-Ind-CA, human papillomavirus-independent cervical adenocarcinoma; *P<0.05.

independent risk factors for PFS and OS in patients with cervical adenocarcinoma. Furthermore, the absence of HPVI and older age of \geq 50 years were also recognized as independent risk factors for OS, all exhibiting statistically significant differences (P < 0.05) (Table 7). Among these patients, low differentiation (hazard ratio

[HR] = 152.673, 95% confidence interval [CI]: 1.777–13117.314, P = 0.027) and high CA199 levels (HR = 104.888, 95% CI: 2.420–4546.373, P = 0.016) were identified as significant independent risk factors for OS in those with HPV-Ind-CA (P < 0.05) (Table 8). In patients with HPV-CA, FIGO stage > I, absence of HPVI, and high

TABLE 4 A comparative analysis of the pathological characteristics of patients with cervical adenocarcinoma in the two groups.

Pathological characteristics	HPV-Ind-CA group	HPV-CA group	χ^2 /fisher	P值		
Diagnosis						
Usual type		255	_	_		
Intestinal-type		9				
G-EAC	30					
Endometrioid adenocarcinoma	6					
Clear cell type	4					
ISMC		1				
Mucinous adenocarcinoma, NOS		20				
Invasive adenocarcinoma, NOS	7					
HPVI						
Yes	5	212	_	_		
No	42	73				
MD [▲] (cm)						
<2	2	19	0.871	0.647		
≥2, <4	13	66				
≥4	30	141				
Differentiation						
High	12	26				
Moderate	18	196	18.617	0.000*		
Low	17	63				

(Continued)

TABLE 4 Continued

Pathological characteristics	HPV-Ind-CA group	HPV-CA group	χ^2 /fisher	 P值
FIGO stage				
Ι	7	98	20.699	
II	15	121		
III	14	42		0.000*
IV	8	14		

FIGO, International Federation of Gynecology and Obstetrics; G-EAC, gastric-type adenocarcinoma; HPV-CA, human papillomavirus-related cervical adenocarcinoma; HPVI, human papillomavirus infection; ISMC, invasive stratified mucinous carcinoma; HPV-Ind-CA, human papillomavirus-independent cervical adenocarcinoma; MD, maximum diameter; NOS, not otherwise specified; A denotes the largest dimension of the neoplasm. *P<0.05.

TABLE 5 A Comparative analysis of therapeutic efficacy and survival outcomes of patients with cervical adenocarcinoma in the two groups.

Evaluation	CR	SD	PD	Dead	Lost to follow up	PFS (month)	OS (month)
HPV-CA	53	143	85	67	4	26 ± 32.34	35 ± 31.93
HPV-Ind-CA	11	17	19	15	0	12 ± 25.48	21 ± 25.11
χ^2	4.233		1.399		5.895	4.695	
P value	0.237			0.237		0.015*	0.030*

CR, complete remission; HPV-CA, human papillomavirus-related cervical adenocarcinoma; HPV-Ind-CA, human papillomavirus-independent cervical adenocarcinoma; OS, overall survival; PD, disease progression; PFS, progression-free survival; SD, stable disease; *P<0.05.

TABLE 6 A summary of the univariate log-rank survival analysis for the two patient groups ($\chi^2).$

TABLE 6 Continued

Factors	PFS		OS	
	χ²	P value	χ²	P value
Age, y				
<50				
≥50	6.435	0.011*	11.74	0.001*
Asian ethnicity				
Han				
Hui	3.531	0.832	4.910	0.671
Uigur				
Manchu				
Kirgiz				
Kazak				
Mongolian				
Dongxiang				
Symptoms				
Abnormal vaginal hemorrhage				
Abnormal vaginal secretion	7.982	0.334	8.409	0.298
Other				

Factors	PFS		OS			
	χ²	P value	χ ²	P value		
None						
Bleeding						
No						
Yes	4.554	0.033*	6.313	0.012*		
Menopause						
No						
Yes	4.716	0.030*	5.189	0.023*		
Correlation with oth	Correlation with other benign uterine lesions					
Adenomyoma						
Leiomyoma	2.252	0.690	1.594	0.810		
Ectopic gestation						
No						
Miscarriage incidence	ce					
<2						
≥2	3.247	0.072	2.288	0.130		
Parity						
<2						
≥2	0.000	0.994	0.283	0.595		

(Continued)

(Continued)

TABLE 6 Continued

Factors	PFS		OS			
	χ ²	P value	χ ²	P value		
Differentiation						
High						
Moderate	11.389	0.003*	12.194	0.002*		
Low						
HPVI						
No						
Yes	10.918	0.001*	15.515	0.000*		
MD (cm)						
<2						
≥2, <4	7.879	0.019*	5.315	0.070		
≥4						
FIGO stage						
Ι						
II	147.892	0.000*	159.883	0.000*		
III						
IV						
CA125						
Normal						
Increase	59.585	0.000*	67.180	0.000*		
CA199						
Normal						
Increase	26.929	0.000*	31.872	0.000*		
CEA						
Normal						
Increase	21.546	0.000*	20.722	0.000*		
Surgery						
Yes						
No	75.555	0.000*	99.741	0.000*		
Adjuvant radiothera	ру					
No						
Yes	1.973	0.160	5.801	0.055		
Adjuvant chemothe	Adjuvant chemotherapy					
No						
Yes	0.039	0.843	2.952	0.086		

HPV-CA, human papillomavirus-related cervical adenocarcinoma; HPVI, human papillomavirus infection; HPV-Ind-CA, human papillomavirus-independent cervical adenocarcinoma; OS, overall survival; PFS, progression-free survival; *P < 0.05.

CA125 levels were identified as independent risk factors influencing OS and PFS. Furthermore, older age \geq 50 years was recognized as an significant independent risk factor affecting OS and high CA199 level affecting PFS (P < 0.05) (Table 9).

Among the 332 patients, the OS rate was 74.1% (246/332) months in the HPV-Ind-CA group, with the mean PFS and OS of 12 ± 25.5 and 21 ± 25.1 months, respectively. Survival analysis revealed that the 3-year OS and PFS rates were 70.21% and 59.57%, respectively. In the HPV-CA group, the mean PFS and OS were 26 ± 32.3 and 35 ± 31.9 months, respectively. Survival analysis revealed that the 3-year OS and PFS rates were 80.70% and 73.68%, respectively. Statistically significant differences in OS and PFS were observed between the two groups of patients with cervical adenocarcinoma. The HPV-CA group demonstrated superior OS ($\chi^2 = 4.695$, P = 0.030) and PFS ($\chi^2 = 5.895$, P = 0.015) compared to the HPV-Ind-CA group. Detailed information can be found in Figures 2, 3.

4 Discussion

With the widespread implementation of cervical cancer screening methods and introduction of cervical cancer vaccines, the incidence of cervical SCC has significantly declined. Compared to cervical squamous epithelial lesions, liquid-based cytology demonstrates a lower detection rate for cervical glandular epithelial lesions. This discrepancy arises from the deeper location of the glandular epithelial lesions within the cervix. Consequently, when collecting samples for cervical cytology, relying solely on surface cell collection may lead to an increased risk of misdiagnosis (11, 12). Consequently, HPV screening and cervical liquid-based cytological assessments have limited utility in the early detection of cervical adenocarcinoma (13). Physicians with inadequate awareness of rare diseases may be unable to identify such conditions promptly during gynecological examinations. Consequently, early diagnosis and intervention are often not realized, contributing to the rising incidence of cervical adenocarcinoma.

The etiology of cervical adenocarcinoma remains unclear. Similar to cervical SCC, it may be associated with several factors as follows: 1) persistent high-risk HPVIs (particularly types 16 and 18); 2) epigenetic alterations, genetic mutations, and dysregulation of the cell cycle; 3) prolonged chronic inflammation leading to changes in the microenvironment that facilitate tumor development and progression; 4) early onset of sexual activity, disordered sexual behaviors among partners, multiple sexual partners, and excessive reproductive history; and 5) obesity, prolonged use of oral contraceptives (exceeding 10 years), and hormone replacement therapy (14, 15). The onset of cervical adenocarcinoma is typically insidious and its clinical manifestations lack specificity. The mean age of the patients at diagnosis is 50 years. Notably, patients with HPV-Ind-CA tend to be older than those with HPV-CA, frequently presenting in the elderly population (16). Irregular



TABLE 7 Multivariate Cox regression analysis of prognostic factors in patients with cervical adenocarcinoma [HR(95%CI)].

Factor	PFS	P value	OS	P value
Age(≥ 50 years)	1.421(0.808-2.497)	0.222	02.538(1.309-4.921)	0.006*
FIGO stage (> I)	1.857(1.251-2.756)	0.002*	2.3329(1.511-3.598)	0.000*
HPVI (No)	0.635(0.380-1.061)	0.083	0.474(0.256-0.877)	0.017*
CA125 (increase)	2.163(1.188-3.937)	0.012*	2.560(1.285-5.097)	0.007*
CA199 (increase)	2.294(1.335-3.944)	0.003*	2.326(1.266-4.275)	0.007*

FIGO, International Federation of Gynecology and Obstetrics; HPVI, human papillomavirus infection; OS, overall survival; PFS, progression-free survival; *P<0.05.

vaginal bleeding often serves as the initial symptom prompting medical consultation (17). The current study revealed that the mean age of the patients diagnosed with cervical adenocarcinoma was 52 years. The majority of patients with HPV-Ind-CA were aged ≥ 50 years (P = 0.001), and most were postmenopausal (P = 0.023), indicating a statistically significant difference from those in the HPV-CA group. Furthermore, 57.83% of patients presented with abnormal vaginal bleeding as their initial symptom, and a substantial proportion exhibited contact bleeding during gynecological examinations, which is consistent with findings from previous studies. In patients with cervical adenocarcinoma, gynecological examinations often reveal cervical hypertrophy and endophytic growth of lesions, which typically have a barrel-shaped appearance. Cervical polyps may also be observed in some patients (18). These lesions predominantly originate from the deep cervical stroma and demonstrate endophytic growth, making them susceptible to misdiagnosis or missed diagnoses before surgery. Their biological behavior is notably more aggressive; compared to SCC, they are more likely to metastasize to the pelvic lymph nodes, invade stromal tissue, and infiltrate deeper into the cervix (19).

Treatment strategies for cervical adenocarcinoma are analogous to those for cervical SCC, and no standardized therapeutic approach is currently available. The 2018 IECC established that HPV-Ind-CA possesses distinct morphological and molecular characteristics associated with poor prognosis and varying potential for future targeted therapies (20). The current study demonstrated that the absence of radical surgery is a significant risk factor for PFS and OS in patients with cervical adenocarcinoma. Therefore, for postmenopausal patients with HPV-Ind-CA with FIGO stage > I, neoadjuvant chemoradiotherapy is a viable option that may enhance the likelihood of surgical resection if the patient's physical condition allows it. In addition to the standard radical hysterectomy and lymphadenectomy, concurrent excision of the greater omentum, appendix, and metastatic lesions is recommended. Postoperatively, concurrent chemoradiotherapy with platinum agents can be augmented with immunosuppressants to improve patient prognosis.

TABLE 8 Multivariate Cox survival analysis of prognostic factors in patients with HPV-Ind-CA [HR 95%CI)].

Factor	PFS	P value	OS	P value
Differentiation (Low)	1.754 (0.614–5.015)	0.294	152.673 (1.777–13117.314)	0.027*
CA199 (Increase)	2.865 (0.575–14.276)	0.199	104.888 (2.420-4546.373)	0.016*

HPV-Ind-CA, human papillomavirus-independent cervical adenocarcinoma; OS, overall survival; PFS, progression-free survival; *P<0.05.

Factor	PFS	P value	OS	P value
Age(≥ 50 years)	1.685(0.908-3.127)	0.098	2.614(1.304-5.242)	0.007*
FIGO stage(> I)	1.689(1.082-2.636)	0.021*	2.381(1.513-3.747)	0.000*
HPVI(No)	0.566(0.323-0.991)	0.047*	0.443(0.231-0.851)	0.014*
CA125 (increase)	2.407(1.280-4.529)	0.006*	2.835(1.371-5.862)	0.005*
CA199 (increase)	2.216(1.191-4.123)	0.012*	-	-

TABLE 9 Multivariable Cox survival analysis of prognostic factors in patients with HPV-CA [HR(95%CI)].

FIGO, International Federation of Gynecology and Obstetrics; HPV-CA, human papillomavirus-related cervical adenocarcinoma; HPVI, human papillomavirus infection; OS, overall survival; PFS, progression-free survival; *P<0.05.

Using the IECC classification, the case data of patients with cervical adenocarcinoma collected in this study were categorized into HPV-Ind-CA and HPV-CA groups for a comparative analysis. The results revealed statistically significant differences between the two groups in several parameters, including age (median age, 56 and 51 years, respectively), menstrual history (menopausal status), degree of differentiation, FIGO staging, variations in the tumor marker CA125, and whether radical surgery was performed (P < 0.05). The HPV-Ind-CA group exhibited greater FIGO staging (P =0.000), lower tumor differentiation (P = 0.000), and higher CA125 levels (P = 0.034). Additionally, most patients in this group were postmenopausal (P = 0.017) and largely unable to undergo radical surgery (P = 0.000). The tumor-related mortality rate was higher in the HPV-Ind-CA group (31.91%, 15/47) than in the HPV-CA group (23.51%, 67/285); however, this difference was not statistically significant (P > 0.05). Furthermore, the findings indicated that OS and PFS were significantly poorer in the HPV-Ind-CA group (χ^2 = 4.695, P = 0.030 and χ^2 = 5.895, P = 0.015, respectively) than in the HPV-CA group, which aligns with previous research findings.

In recent years, a growing body of literature on cervical adenocarcinoma has indicated that the factors influencing its

prognosis include age, HPV infection subtype, clinical stage, histological subtype, maximum tumor diameter, stromal invasion, presence of a vascular tumor thrombus, surgical resection margin status, and ovarian and lymph node metastases. However, no definitive conclusion has been reached. Lijie et al. (21) conducted a study examined the correlation between HPVI subtypes, viral load, and the clinicopathological characteristics of cervical adenocarcinoma and reported that HPV-Ind-CA was associated with either an absence of viral infection or a lower viral load than HPV-CA. Furthermore, low viral loads observed in cases of multiple infections were identified as significant factors contributing to poor survival prognosis. We conducted a log-rank univariate survival analysis to assess HPVI status in the two patient groups. The results revealed that the absence of HPVI constituted an independent risk factor for OS in cervical adenocarcinoma (HR = 0.474, 95% CI: 0.256 - 0.877, P = 0.017), thereby further corroborating the aforementioned research findings. Previous studies have indicated that HPV-Ind-CA is diagnosed at a more advanced stage and is associated with higher rates of lymph node metastasis, reduced PFS and OS, and poorer prognosis (22). G-EAC, the most prevalent subtype of HPV-Ind-CA, is more aggressive than usual type cervical adenocarcinoma. More than





40% of patients are diagnosed with G-EAC at an intermediate or advanced stage of the disease (23). This could potentially be attributed to the reduced predictive capacity of negative HPV tests for cervical cancer, thereby resulting in the failure of timely detection of the disease at the early stage (24). The study further revealed that the 5-year survival rate for common cervical adenocarcinoma reached 91%, whereas that for G-EAC was only 42%. In addition, a higher FIGO stage was associated with poorer PFS and OS. The current study identified FIGO stage beyond Stage I as an independent risk factor for PFS and OS in patients with cervical adenocarcinoma, thereby corroborating previous findings.

Currently, research investigating the correlation between tumor markers and cervical adenocarcinoma has increased significantly, with particular emphasis on CA-125 and CA19-9. Although these markers have traditionally been regarded as important indicators for ovarian epithelial tumors, their roles in cervical adenocarcinoma are now receiving increasing attention. Previous studies indicated that approximately half of the patients with G-EAC exhibited high CA199 levels, and approximately one-third had high CA125 levels, and an increase in CA125 is often indicative of pelvic and abdominal metastasis (25). Once again, Jack et al. (26) conducted a retrospective analysis of the clinical data from 572 patients with International Federation of FIGO stage IA-IIA cervical adenocarcinoma and found that Stratified analysis showed that elevated CA125 and CA199 were significantly associated with postoperative distant metastasis. And a decision curve analysis confirmed that a combination of tumor markers as predictors significantly outperformed the other common predictors used (FIGO-stage, intermediate and high-risk factors, tumor differentiation, lymph nodes). The aforementioned research outcomes unanimously demonstrate that a significant correlation exists between the tumor markers CA125 and CA199 and the diagnosis and prognosis of cervical adenocarcinoma. In the comparative analysis of tumor markers between the two groups, we observed that a higher proportion of patients in the HPV-Ind-CA group exhibited high CA125 levels than those in the HPV-CA group. Additionally, high CA125 and CA199 levels were identified as independent risk factors for PFS and OS in cervical adenocarcinoma, suggesting that increased serum levels of CA125 and CA199 may serve as prognostic biomarkers for poor outcomes in this condition (27), and the findings of this research might offer significant evidence in support of the application of preoperative serum CA-125 and CA19-9 detection in the prognosis evaluation of cervical adenocarcinoma. however, further validation is necessary through studies involving larger sample sizes.

A major limitation of this study was the relatively limited sample size. Currently, there is a paucity of research on HPV-Ind-CA, globally, and the existing literature is insufficient. Further large-scale multicenter studies are necessary to comprehensively investigate the clinicopathological characteristics and prognostic differences between HPV-Ind-CA and HPV-CA, as well as to enhance awareness regarding cervical adenocarcinoma. Early identification, diagnosis, and treatment strategies are essential for improving the survival outcomes of patients with cervical adenocarcinoma.

Cervical adenocarcinoma is characterized by concealed anatomical location and deep-seated lesions, accompanied by atypical clinical symptoms and signs, which complicate its early detection. The findings of this study suggest that clinicians must consider seeking cervical glandular epithelial lesions when patients present with abnormal vaginal bleeding or discharge. During gynecological examinations, meticulous attention should be paid to the morphology of the cervix to assess characteristics, such as barrel-shaped enlargement, thickening, hypertrophy, or increased firmness. If indicated, enhanced magnetic resonance imaging (28), multiple colposcopic deep biopsies (29), or cervical conization may be used to elucidate the nature of the lesions for timely identification and diagnosis. For patients with a confirmed diagnosis of cervical adenocarcinoma without HPV infection, who are aged ≥50 years and have FIGO staging > I along with high CA125 and CA199 levels, it is imperative to implement standardized treatment protocols and conduct regular follow-up assessments to optimize survival outcomes.

In conclusion, compared with HPV-CA, HPV-Ind -CA is a heterogeneous tumor characterized by distinct clinical and molecular mechanisms. Owing to its rarity and negative HPV test results, it lacks specific clinical manifestations, is often overlooked by clinicians, complicates early diagnosis, has a high rate of misdiagnosis, is susceptible to invasion and metastasis, demonstrates insensitivity to radiotherapy and chemotherapy, and has a poor prognosis. However, there are currently no tailored treatment protocols for cervical adenocarcinoma that consider the HPV status or various histological subtypes in clinical practice. Understanding the clinicopathological features of patients with cervical adenocarcinoma who present with these risk factors will significantly aid in early detection, diagnosis, and management of this type of tumor. Additionally, efforts should be made to maximize surgical opportunities for patients to improve their survival outcomes.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Oncology Hospital Affiliated with Xinjiang Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

JH: Conceptualization, Writing – original draft. GT: Writing – review & editing. LZ: Funding acquisition, Resources, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Acknowledgments

We are deeply grateful to Xinjiang Medical University Cancer Hospital for offering the data that enabled this study to proceed. Additionally, I sincerely thank the three authors for their strenuous efforts, and I also wish to recognize the work of previous researchers, which permitted us to build upon their discoveries and draw more significant conclusions.

References

1. Liverani CA, Di Giuseppe J, Giannella L, Delli Carpini G, Ciavattini A. Cervical cancer screening guidelines in the postvaccination era: Review of the literature. *J Oncol.* (2020) 2020:8887672. doi: 10.1155/2020/8887672

2. Abbas KM, Van Zandvoort K, Brisson M, Mark J. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. *Lancet Global Health*. (2020) 8:e536–e544. doi: 10.1016/S2214-109X(20)30022-X

3. Xi-he YU, Jingru Z, Hairui J, Panpan S, Shang G. Disease burden of cervical cancer and breast cancer in Chinese women in 1990 and 2019. *Chin J Of Public Health.* (2022) 38:534–8. doi: 10.11847/zgggws1136776

4. Ting-ting XU, Xingtian Z, Xiaoning He Jing W. Disease burden of cervical cancer in Belt and Road surrounding countries in 2018. *Chin J Of Public Health.* (2023) 39:1311–4. doi: 10.11847/zgggws1142282

5. Giannella L, Giorgi Rossi P, Delli Carpini G, Di Giuseppe J, Bogani G, Gardella B, et al. Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. *Gynecol Oncol.* (2021) 161:741–7. doi: 10.1016/j.ygyno.2021.03.025

6. Jenkins D, Molijn A, Kazem S, Pirog EC, Alemany L, de Sanjosé S, et al. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. *Int J Cancer.* (2020) 147:2526–36. doi: 10.1002/ijc.33124

7. Kugelman N, Siegler E, Mackuli L, Lavie O, Schmidt M, Shaked-Mishan P, et al. Prognosis of human papillomavirus-negative compared to human papillomaviruspositive cervical cancer. *J Low Genit Tract Dis.* (2022) 26:115–21. doi: 10.1097/ LGT.000000000000650

8. Giannella L, Di Giuseppe J, Delli Carpini G, Grelloni C, Fichera M, Sartini G, et al. HPV-negative adenocarcinomas of the uterine cervix: From molecular characterization to clinical implications. *Int J Mol Sci.* (2022) 23. doi: 10.3390/ijms232315022

9. Zong L, Chen J. Research advances in the pathological classification and typing of cervical adenocarcinoma. *Prog Obstet Gynecol.* (2020) 29:543–5. doi: 10.13283/j.cnki.xdfckjz

10. Hu K, Wang W, Liu X, Meng Q, Zhang F. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. *Radiat Oncol.* (2018) 13:249. doi: 10.1186/ s13014-018-1197-5

11. Liang Z, Xia T. Analysis of the incidence trends and clinical characteristics of inpatients with cervical adenocarcinoma in the past 10 years. *J Pract Obstet Gynecol.* (2017) 33:838–43.

 Castillo M, Astudillo A, Clavero O, Velasco J, Ibáñez R, de Sanjosé S. Poor cervical cancer screening attendance and false negatives. A call for organized screening. *PLoS One*. (2016) 11:e0161403. doi: 10.1371/journal.pone.0161403

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

13. Aijuan H, Xiaowei L, Mingzhu L, Lijun Z, Chao Z, Shuhui C, et al. Analysis of the clinical characteristics of 61 cases of cervical glandular lesions. *Chin J Clin Obstet Gynecol.* (2018) 19:345–7. doi: 10.13390/j.issn.1672-1861.2018.04.015

14. Shujing Z, Lixin S, Yuqin C. A comparative study on the clinicopathological characteristics and prognosis of human papillomavirus-associated and nonhuman papillomavirus-associated cervical adenocarcinoma[J/OL. *Chin Gen Pract.* (2024) 1–8. (2024-12-01). Available online at: http://kns.cnki.net/kcms/detail/13.1222.r.20240822. 1628.022.html.

15. Songge L, Jianfa G, Qiong P, Shanyong Y. The expression of vascular endothelial growth factor and basic fibroblast growth factor in cervical cancer and their relationship with microvessel density. *Oncol Prog.* (2021) 19:1697–700.

16. Turashvili G, Park KJ. Cervical glandular neoplasia: Classification and Staging. Surg Pathol Clin. (2019) 12:281–313. doi: 10.1016/j.path.2019.01.002

17. Yue L, Kuiran L. Analysis of the clinical characteristics of 63 cases of special-type cervical adenocarcinoma. *Prog Obstet Gynecol.* (2022) 31:401-6. doi: 10.13283/j.cnki.xdfckjz.2022.06.031

18. Miao M, Gailin L, Yanpeng T, Q Z. Comparative analysis of diagnosis and treatment between cervical gastric-type adenocarcinoma and common cervical adenocarcinoma. *Henan J Surg.* (2023) 29:63–7. doi: 10.16193/j.cnki.hnwk.2023.03.071.

19. Alméciga A, Rodriguez J, Beltrán J, Sáenz J, Merchán A, Egurrola J, et al. Emergency embolization of pelvic vessels in patients with locally advanced cervical cancer and massive vaginal bleeding: A case series in a Latin American oncological center. *JCO Glob Oncol.* (2020) 6:1376–83. doi: 10.1200/GO.20.00239

20. Hodgson A, Olkhov-Mitsel E, Howitt BE, Nucci MR, Parra-Herran C. International Endocervical adenocarcinoma Criteria and Classification (IECC): Correlation with adverse clinicopathological features and patient outcome. *J Clin Pathol.* (2019) 72:347–53. doi: 10.1136/jclinpath-2018-205632

21. Lijie C. A Study on the Correlation of HPV Infection Subtypes and Viral Load with the Clinicopathological Characteristics of Cervical Adenocarcinoma. Bengbu City, Anhui Province, China: Bengbu Medical University (2023).

22. Xiong Y, Jing L. Research progress on non-HPV-associated cervical adenocarcinoma. *Prog Obstet Gynecol.* (2024) 33:385-8 + 392. doi: 10.13283/j.cnki.xdfckjz.2024.05.032

23. Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, et al. Gastric-type endocervical adenocarcinoma: An aggressive tumor with unusual metastatic patterns and poor prognosis. *Am J Surg Pathol.* (2015) 39:1449–57. doi: 10.1097/PAS.00000000000532

24. Dai W, Zeng X, Pantanowitz L, Zhao C. Human papillomavirus negative cervical cancers and precancerous lesions: prevalence, pathological and molecular features, and

clinical implications. Gynecology Obstetrics Clin Med. (2025) 5. doi: 10.1136/gocm-2024-000160

25. Huang ZY, Zhang S, Zhang YZ, An JH, Luo J, Liao PJ, et al. The clinicopathologic and immunohistochemical features of villoglandular adenocarcinoma of uterine cervix. *Indian J Pathol Microbiol.* (2018) 61:549–52. doi: 10.4103/IJPM.IJPM_144_18

26. Zhang Z, Li Y, Wu Y, Rui B, Xiaohua W, Guihao K, et al. Identifying tumor markers-stratified subtypes (CA-125/CA19-9/carcinoembryonic antigen) in cervical adenocarcinoma. *Int J Biol Markers*. (2023) 38:223–32. doi: 10.1177/03936155231206839

27. Guo P, Liu P, Yang J, Ren T, Xiang Y. Villoglandular adenocarcinoma of cervix: Pathologic features, clinical management, and outcome. *Cancer Manag Res.* (2018) 10:3955–61. doi: 10.2147/CMAR.S165817

28. Ohya A, Kobara H, Miyamoto T, Komatsu M, Shiozawa T, Fujinaga Y. Usefulness of the 'cosmos pattern' for differentiating between cervical gastric-type mucin-positive lesions and other benign cervical cystic lesions in magnetic resonance images. J Obstet Gynaecol Res. (2021) 47:745–56. doi: 10.1111/jog.14602

29. Xie Y, Zhou Q, Chen L, Sui L. Pathology behind constant watery vaginal discharge: A rare case of uterine cervical minimal deviation adenocarcinoma. *Cancer Manag Res.* (2021) 13:7929–35. doi: 10.2147/CMAR.S334660